September 27, 2021 10:29 AM EDT

Biogen can't escape copay kickback lawsuits as Humana alleges 'seeding and sweeping' scheme

Amber Tong

The Department of Justice made an example out of Biogen when it resolved allegations the drugmaker concocted a scheme to lure patients into taking its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biogen can't escape copay kickback lawsuits as Humana alleges 'seeding and sweeping' scheme

Amber Tong

Sign up to read this article for free.

Scott Gottlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this country’

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

FDA defends increased use of guidance in new report to Congress

Sanofi earmarks €1B for new insulin production factory in Beijing

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Agenus launches biologics manufacturing business to generate cash

Bio­gen can't es­cape co­pay kick­back law­suits as Hu­mana al­leges 'seed­ing and sweep­ing' scheme

Amber Tong

Sign up to read this article for free.

more like this

Scott Got­tlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this coun­try’

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

FDA de­fends in­creased use of guid­ance in new re­port to Con­gress

Sanofi ear­marks €1B for new in­sulin pro­duc­tion fac­to­ry in Bei­jing

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

Agenus launch­es bi­o­log­ics man­u­fac­tur­ing busi­ness to gen­er­ate cash

Biogen can't escape copay kickback lawsuits as Humana alleges 'seeding and sweeping' scheme

Scott Gottlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this country’

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

FDA defends increased use of guidance in new report to Congress

Sanofi earmarks €1B for new insulin production factory in Beijing

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Agenus launches biologics manufacturing business to generate cash